Details of the Drug

General Information of Drug (ID: DMR6N7H)

• Drug Name: Acetohexamide
• Synonyms: Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]

• Therapeutic Class: Hypoglycemic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 324.4
  Logarithm of the Partition Coefficient (xlogp); 2.4
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption: The drug is rapidly absorbed from the gastrointestinal tract []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1.3 hours [3]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 77.06496 micromolar/kg/day [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 3.43 mg/mL [2]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Metabolic disorder	Not Available	CBR3	OT9G6SF0	[5]

• Chemical Identifiers:
  Formula: C15H20N2O4S
  IUPAC Name: 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea
  Canonical SMILES: CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2
  InChI: InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
  InChIKey: VGZSUPCWNCWDAN-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 1989
  ChEBI ID: CHEBI:28052
  CAS Number: 968-81-0
  DrugBank ID: DB00414
  TTD ID: D07WFK
  VARIDT ID: DR01113
  INTEDE ID: DR0039

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-binding cassette transporter C8 (ABCC8)	TTP835K	ABCC8_HUMAN	Modulator	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[7]
Short-chain dehydrogenase/reductase retSDR1 (DHRS3)	DEXPVUN	DHRS3_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[9]
Carbonyl reductase 3 (CBR3)	OT9G6SF0	CBR3_HUMAN	Drug Response	[5]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Acetohexamide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Acetohexamide caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[10]

Coadministration of a Drug Treating the Disease Different from Acetohexamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Acetohexamide due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[11]
Tromethamine	DMOBLGK	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Acetohexamide caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[12]
Oxandrolone	DMU9MYJ	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Oxandrolone.	Alcoholic liver disease [DB94]	[13]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Oxymetholone.	Aplastic anaemia [3A70]	[14]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Acetohexamide caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[13]
Clarithromycin	DM4M1SG	Moderate	Increased plasma concentration of Acetohexamide and Clarithromycin due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[15]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[14]
Chloramphenicol	DMFXEWT	Moderate	Increased plasma concentration of Acetohexamide and Chloramphenicol due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[16]
Linezolid	DMGFPU2	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Linezolid.	Bacterial infection [1A00-1C4Z]	[13]
Nitazoxanide	DMOWLVG	Moderate	Increased plasma concentration of Acetohexamide and Nitazoxanide due to competitive binding of plasma proteins.	Bowel habit change [ME05]	[17]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Acetohexamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[13]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[13]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Ketoprofen.	Chronic pain [MG30]	[13]
Ardeparin	DMYRX8B	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Ardeparin.	Coronary thrombosis [BA43]	[13]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Acetohexamide caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[19]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Acetohexamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[20]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Acetohexamide caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[21]
Sertraline	DM0FB1J	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Sertraline.	Depression [6A70-6A7Z]	[13]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Fluoxetine.	Depression [6A70-6A7Z]	[13]
Vilazodone	DM4LECQ	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Vilazodone.	Depression [6A70-6A7Z]	[13]
Selegiline	DM6034S	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Selegiline.	Depression [6A70-6A7Z]	[13]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Vortioxetine.	Depression [6A70-6A7Z]	[13]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Isocarboxazid.	Depression [6A70-6A7Z]	[13]
Escitalopram	DMFK9HG	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Escitalopram.	Depression [6A70-6A7Z]	[13]
Tranylcypromine	DMGB5RE	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Tranylcypromine.	Depression [6A70-6A7Z]	[14]
Phenelzine	DMHIDUE	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Phenelzine.	Depression [6A70-6A7Z]	[13]
PMID28454500-Compound-96	DM2A75P	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and PMID28454500-Compound-96.	Discovery agent [N.A.]	[13]
SODIUM CITRATE	DMHPD2Y	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Acetohexamide caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[12]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and PMID28870136-Compound-49.	Discovery agent [N.A.]	[13]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Mefenamic acid.	Female pelvic pain [GA34]	[13]
Miconazole	DMPMYE8	Major	Decreased metabolism of Acetohexamide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Nizatidine	DMGFV3Z	Moderate	Decreased absorption of Acetohexamide due to altered gastric pH caused by Nizatidine.	Gastro-oesophageal reflux disease [DA22]	[22]
Cimetidine	DMH61ZB	Moderate	Decreased absorption of Acetohexamide due to altered gastric pH caused by Cimetidine.	Gastro-oesophageal reflux disease [DA22]	[22]
Sunitinib	DMCBJSR	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Acetohexamide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[23]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Acetohexamide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[24]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Acetohexamide caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Gemfibrozil	DMD8Q3J	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[13]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[13]
Moexipril	DM26E4B	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Moexipril.	Hypertension [BA00-BA04]	[13]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Captopril.	Hypertension [BA00-BA04]	[13]
Trandolapril	DM4L6EU	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Trandolapril.	Hypertension [BA00-BA04]	[13]
Methyldopa	DM5I621	Minor	Decreased metabolism of Acetohexamide caused by Methyldopa.	Hypertension [BA00-BA04]	[26]
Fosinopril	DM9NJ52	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Fosinopril.	Hypertension [BA00-BA04]	[13]
Benazepril	DMH1M9B	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Benazepril.	Hypertension [BA00-BA04]	[13]
Enalapril	DMNFUZR	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Enalapril.	Hypertension [BA00-BA04]	[13]
Perindopril	DMOPZDT	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Perindopril.	Hypertension [BA00-BA04]	[13]
Quinapril	DMR8H31	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Quinapril.	Hypertension [BA00-BA04]	[13]
Lisinopril	DMUOK4C	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Lisinopril.	Hypertension [BA00-BA04]	[13]
Sodium acetate anhydrous	DMH21E0	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Acetohexamide caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[12]
Probenecid	DMMFWOJ	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[13]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[14]
Testosterone	DM7HUNW	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Testosterone.	Low bone mass disorder [FB83]	[13]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Acetohexamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[27]
Chloroquine	DMSI5CB	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Chloroquine.	Malaria [1F40-1F45]	[13]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[13]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[13]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Acetohexamide caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[23]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Acetohexamide and Methoxsalen.	Mycosis fungoides [2B01]	[27]
Diclofenac	DMPIHLS	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Diclofenac.	Osteoarthritis [FA00-FA05]	[13]
Naproxen	DMZ5RGV	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Naproxen.	Osteoarthritis [FA00-FA05]	[13]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[14]
Aspirin	DM672AH	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Aspirin.	Pain [MG30-MG3Z]	[14]
Etodolac	DM6WJO9	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Etodolac.	Pain [MG30-MG3Z]	[13]
Diflunisal	DM7EN8I	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Diflunisal.	Pain [MG30-MG3Z]	[13]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Ibuprofen.	Pain [MG30-MG3Z]	[13]
Nabumetone	DMAT2XH	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Nabumetone.	Pain [MG30-MG3Z]	[13]
Piroxicam	DMTK234	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Piroxicam.	Pain [MG30-MG3Z]	[13]
Safinamide	DM0YWJC	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Safinamide.	Parkinsonism [8A00]	[13]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Rasagiline.	Parkinsonism [8A00]	[13]
Ranitidine	DM0GUSX	Moderate	Decreased absorption of Acetohexamide due to altered gastric pH caused by Ranitidine.	Peptic ulcer [DA61]	[22]
Esomeprazole	DM7BN0X	Minor	Decreased metabolism of Acetohexamide caused by Esomeprazole mediated inhibition of CYP450 enzyme.	Peptic ulcer [DA61]	[28]
Famotidine	DMRL3AB	Moderate	Decreased absorption of Acetohexamide due to altered gastric pH caused by Famotidine.	Peptic ulcer [DA61]	[22]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[14]
Ketorolac	DMI4EL5	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Ketorolac.	Postoperative inflammation [1A00-CA43]	[13]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Acetohexamide and Verteporfin.	Psoriasis [EA90]	[29]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Acetohexamide caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[30]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Salsalate.	Rheumatoid arthritis [FA20]	[13]
Meloxicam	DM2AR7L	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Meloxicam.	Rheumatoid arthritis [FA20]	[13]
Sulindac	DM2QHZU	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Sulindac.	Rheumatoid arthritis [FA20]	[13]
Celecoxib	DM6LOQU	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Celecoxib.	Rheumatoid arthritis [FA20]	[13]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Oxaprozin.	Rheumatoid arthritis [FA20]	[13]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Flurbiprofen.	Rheumatoid arthritis [FA20]	[13]
Sulfasalazine	DMICA9H	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Sulfasalazine.	Rheumatoid arthritis [FA20]	[13]
Fenoprofen	DML5VQ0	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Fenoprofen.	Rheumatoid arthritis [FA20]	[13]
Leflunomide	DMR8ONJ	Moderate	Decreased metabolism of Acetohexamide caused by Leflunomide mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[31]
Tolmetin	DMWUIJE	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Tolmetin.	Rheumatoid arthritis [FA20]	[13]
Cyclophosphamide	DM4O2Z7	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Cyclophosphamide.	Solid tumour/cancer [2A00-2F9Z]	[13]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[13]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[13]
Pramlintide	DM0EZ9Q	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Pramlintide.	Type-1/2 diabete [5A10-5A11]	[13]
Olsalazine	DMZW9HA	Moderate	Increased risk of hypoglycemia by the combination of Acetohexamide and Olsalazine.	Ulcerative colitis [DD71]	[13]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6793).
• [2] BDDCS applied to over 900 drugs
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [6] Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
• [7] Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
• [8] Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 2015 Jun 5;234:178-87.
• [9] Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1590-8. doi: 10.1016/j.jchromb.2010.04.019.
• [10] Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
• [11] Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
• [12] Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
• [13] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [14] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
• [15] Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
• [16] Brunova E, Slabochova Z, Platilova H, Pavlik F, Grafnetterova J, Dvoracek K "Interaction of tolbutamide and chloramphenicol in diabetic patients." Int J Clin Pharmacol 15 (1977): 7-12. [PMID: 838527]
• [17] Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
• [18] Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
• [19] Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
• [20] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [21] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [22] Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
• [23] Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
• [24] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [25] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [26] Gachalyi B, Tornyossy, Vas A, Kaldor A "Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man." Int J Clin Pharmacol Ther Toxicol 18 (1980): 133-5. [PMID: 6103880]
• [27] Cerner Multum, Inc. "Australian Product Information.".
• [28] Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
• [29] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [30] Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
• [31] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.